Epithalon vs Epitalon: what the published research shows

One peptide, several names

The story starts with Epithalamin, an extract of bovine pineal gland studied in Russia by V.K. Khavinson and V.N. Anisimov. Researchers then designed a short synthetic peptide based on the amino-acid make-up of that extract: Ala-Glu-Asp-Gly, often shortened to AEDG. That synthetic peptide is Epitalon, also spelled Epithalon or Epithalone, and its synthesis was patented in Russia in 2000.

For years, nobody knew whether AEDG actually occurs in the body. That changed in 2017, when it was detected for the first time in pineal gland extract by liquid chromatography-mass spectrometry. So when you see Epithalon, Epitalon, Epithalone or AEDG peptide, all four names describe the same four-amino-acid sequence with a molecular weight of 390.3 g/mol. Epithalamin, by contrast, is the original extract, not the synthetic peptide.

Telomeres and cell lifespan

Telomeres are the protective caps on the ends of chromosomes. They shorten each time a cell divides, and most normal cells eventually stop dividing, a point known as the Hayflick limit. Telomerase is the enzyme that can rebuild them.

Epithalon's best-known result is its effect on this system. In 2003, adding it to human fetal fibroblasts, which normally have no telomerase activity, switched on the enzyme's catalytic subunit, produced telomerase activity and lengthened telomeres. In a follow-up study, lung fibroblasts that had lost their ability to divide at passage 34 regained telomere length comparable to younger cells. They then made 10 extra divisions compared with untreated cells, and were still dividing at passage 44.

For years these results came mainly from one research group. In 2025, researchers at Brunel University London tested Epitalon in normal human epithelial cells and fibroblasts, and in breast cancer cell lines. In the normal cells, they found dose-dependent telomere lengthening driven by increased hTERT (the telomerase gene) and telomerase activity. In the cancer cell lines, telomeres also lengthened, but through a different route called ALT, which does not rely on telomerase.

Melatonin, the body clock and animal lifespan

Because it comes from pineal research, Epitalon has also been studied in relation to melatonin, the pineal hormone that helps set the body clock. In older monkeys aged 20 to 27, it stimulated melatonin production and helped normalise the daily rhythm of cortisol, while young monkeys were largely unaffected. In a placebo-controlled study in 75 women, urinary markers of melatonin production rose 1.6-fold compared with placebo, alongside changes in the activity of several body-clock genes.

In animal lifespan research, female mice carrying the HER-2/neu breast cancer gene received Epithalon from their second month of life. Average lifespan rose by 13.5% and maximum lifespan by 13.9%. The treated mice also had fewer breast tumours: 3.7 times as many mice stayed free of breast tumours, and lung metastases fell 1.6-fold.

Researchers have also studied Epitalon in the eye. A 2025 review describes a study in 162 patients with retinitis pigmentosa, an inherited eye disease, in which treated patients showed improvements in retinal activity, visual acuity and visual field, and no side effects were reported.

Epithalon vs Pinealon at a glance

Pinealon is often mentioned alongside Epithalon because both are short synthetic peptides from the same Russian research tradition. It is a different molecule, though: a three-amino-acid peptide studied mainly for protecting nerve cells against oxidative stress. In cell studies it reduced the build-up of reactive oxygen species and cell death, and in rats it improved learning in offspring exposed to high homocysteine before birth.

Where the research stands

Epitalon has 25 years of research behind it, mostly in cells and animals, and much of it from the St Petersburg group that developed it. Independent work such as the 2025 Brunel study is newer. The human studies are small and were run in Russia. A 2025 review noted that information on safety is missing from the published work, and that studies of short- and long-term toxicity would be needed before it could be approved as a medicine. Short peptides like Epitalon also tend to break down quickly in the body.

Neither Epitalon nor Pinealon is an approved medicine, including in Australia. Neither is named on the WADA Prohibited List, but WADA's S0 category bans any substance without approval from a government health regulator for human therapeutic use, so anyone subject to testing should assume both are covered.

Sources

• Araj et al., Int J Mol Sci (2025) — Overview of Epitalon, a highly bioactive pineal tetrapeptide
• Khavinson et al., Bull Exp Biol Med (2003) — Epithalon induces telomerase activity and telomere elongation in human somatic cells
• Khavinson et al., Bull Exp Biol Med (2004) — Peptide promotes overcoming of the division limit in human somatic cells
• Al-Dulaimi et al., Biogerontology (2025) — Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity
• Anisimov et al., Bull Exp Biol Med (2002) — Epithalon decelerates ageing and suppresses breast adenocarcinomas in HER-2/neu mice
• Khavinson et al., Rejuvenation Res (2011) — Pinealon increases cell viability by suppressing free radical levels
• Arutjunyan et al., Int J Clin Exp Med (2012) — Pinealon protects rat offspring from prenatal hyperhomocysteinemia
• WADA — The Prohibited List
• PubChem — Epitalon (CID 219042)
• PubChem — Pinealon (CID 10273502)